SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 22, 2005

SIGA TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-23047	13-3864870
(State or other jurisdiction of incorporation or organization)	(Commission file number)	(I.R.S. employer identification no.)

420 Lexington Avenue, Suite 408
New York, New York 10170
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (212) 672-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On September 22, 2005, SIGA Technologies, Inc., a Delaware corporation ("SIGA"), entered into a $3.2 million, one-year agreement with the United States Army Medical Research and Material Command ("USAMRMC"). The agreement, for the rapid identification and treatment of anti-viral diseases, is funded through the United States Air Force ("USAF"). SIGA's efforts will aid the USAF Special Operations Command in its use of computational biology to design and develop specific countermeasures against the biological threat agents Smallpox and Adenovirus. Smallpox is a Center for Disease Control and Prevention (CDC) Category A biothreat agent, and Adenovirus is a cause of significant respiratory infectious disease, both of which may impair the combat readiness of USAF Personnel. A copy of the agreement is attached hereto as exhibit 10.1, which is incorporated into this Item 1.01 by reference.

On September 27, 2005, SIGA issued a press release announcing that it had entered into the agreement with USAMRMC. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit No.	Description
10.1	Agreement, dated as of September 22, 2005, between the United States Army Medical Research and Material Command and SIGA.
99.1	Press Release, dated September 27, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

Name: Thomas N. Konatich
Title: Chief Financial Officer

Date: September 27, 2005

AWARD/CONTRACT	1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 350)	RATING	PAGE OF PAGES
			1 11

2. CONTRACT (Proc. Inst Ident.) NO. W81XWH-05-2-0085	3. EFFECTIVE DATE 22 Sep 2005	4. REQUISITION/PURCHASE REQUEST/PROJECT NO. W81XWH-5101-M260

5. ISSUED BY CODE W81XWH	6. ADMINISTERED BY (If other than Item 5) CODE W81XWH
USA MED RESEARCH ACQ ACTIVITY 820 CHANDLER ST FORT DETRICK MD 21702-5014	USA MED RESEARCH ACQ ACTIVITY ATTN: JUANITA BOURNE 301-619-7426 FORT DETRICK MD 21702

7. NAME AND ADDRESS OF CONTRACTOR (No., street, city, county, state and zip code)	8. DELIVERY [ ] FOB ORIGIN [X] OTHER (See below)
SIGA TECHNOLOGIES INC DENNIS E. HRUBY, PH.D. 420 LEXINGTON AVE RM 408 NEW YORK NY 10170-0499	9. DISCOUNT FOR PROMPT PAYMENT Net 7
	10. SUBMIT INVOICES 0 ITEM (4 copies unless otherwise specified) TO THE ADDRESS SHOWN IN:
CODE 1V4X4 FACILITY CODE	

11. SHIP TO/MARK FOR CODE W23RYX	12. PAYMENT WILL BE MADE BY CODE HQ0345
USA MED RESEARCH AND MATERIEL COM JUANITA LIVINGSTON 504 SCOTT STREET FORT DETRICK MD 21702-5012	DEFENSE FINANCE AND ACCOUNTING SERVICE DFAS-SA/FPA 500 MCCULLOUGH AVENUE PHONE: 888-478-5636 FAX: 866-636-2715 SAN ANTONIO TX 78215-2100

13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION:	14. ACCOUNTING AND APPROPRIATION DATA
[ ] 10 U.S.C. 2304(c)( ) [ ] 41 U.S.C. 253(c)( )	See Schedule

15A. ITEM NO.	15B. SUPPLIES/ SERVICES	15C. QUANTITY	15D. UNIT	15E. UNIT PRICE	15F. AMOUNT
	SEE SCHEDULE				

15G. TOTAL AMOUNT OF CONTRACT $3,200,000.00

16. TABLE OF CONTENTS

(X) SEC.	DESCRIPTION	PAGE(S)	(X) SEC.	DESCRIPTION	PAGE(S)
	PART I - THE SCHEDULE			PART II - CONTRACT CLAUSES	
X A	SOLICITATION/ CONTRACT FORM	1		I CONTRACT CLAUSES	
B	SUPPLIES OR SERVICES AND PRICES/ COSTS			PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS	
C	DESCRIPTION/ SPECS./ WORK STATEMENT			J LIST OF ATTACHMENTS	
D	PACKAGING AND MARKING			PART IV - REPRESENTATIONS AND INSTRUCTIONS	
E	INSPECTION AND ACCEPTANCE			K REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS	
F	DELIVERIES OR PERFORMANCE				
G	CONTRACT ADMINISTRATION DATA			L INSTRS., CONDS., AND NOTICES TO OFFERORS	
H	SPECIAL CONTRACT REQUIREMENTS			M EVALUATION FACTORS FOR AWARD	

CONTRACTING OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE

17. [ ] CONTRACTOR'S NEGOTIATED AGREEMENT	18. [X] AWARD (Contractor is not required to sign this document.)
Contractor is required to sign this document and return copies to issuing office.) Contractor agrees to furnish and deliver all items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein. (Attachments are listed herein.)	Your offer on Solicitation Number _____ REF: See Paragraph A, Page 4 including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the items listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government's solicitation and your offer, and (b) this award/contract. No further contractual document is necessary.

19A. NAME AND TITLE OF SIGNER (Type or print)	20A. NAME AND TITLE OF CONTRACTING OFFICER
	REBECCA J. TAMA / CONTRACTING OFFICER TEL: 301-619-2381 EMAIL:rebecca.tama@det.amedd.army.mil
19B. NAME OF CONTRACTOR 19C. DATE SIGNED	20B. UNITED STATES OF AMERICA 20C. DATE SIGNED
BY (Signature of person authorized to sign)	BY /s/ Rebecca J. Tama 22-Sep-2005 (Signature of Contracting Officer)

Section 00010 - Solicitation Contract Form

ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
0001	Proposal Log No.: 05189001 COST Period of Performance: 26 September 2005 through 25 October 2006 (Research ends 25 September 2006) PURCHASE REQUEST NUMBER: W81XWH-5101-M260				
				ESTIMATED COST	$3,200,000.00
	ACRN AA Funded Amount				$3,200,000.00

FOB: Destination

DELIVERY INFORMATION

CLIN	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
0001	POP 26-SEP-2005 TO 25-OCT-2006	N/A	USA MED RESEARCH AND MATERIEL COM JUANITA LIVINGSTON 504 SCOTT STREET FORT DETRICK MD 21702-5012 FOB: Destination	W23RYX

Section 00800 - Special Contract Requirements

ACCOUNTING AND APPROPRIATION DATA

AA: 21520400000074811266580 1M02IM25GYP1H4IMF1ATD45087G003H4IMP1018064
AMOUNT: $3,200,000.00

CLAUSES INCORPORATED BY FULL TEXT

A. This award is made under the authority of 31 U.S.C. 6305 and 10 U.S.C. 2358. The recipient's statement of work on pages 11-12 of the proposal dated 5 July 2005 and revised budget dated 15 July 2005 which are incorporated herein by reference. The Catalog of Federal Domestic Assistance Number relative to this award is CFDA 12.420.

GOVERNMENT INTERACTION (NOV 2000) (USAMRAA)The active participants in this award are the U.S. Army Medical Research and Materiel Command (USAMRMC) and its laboratories identified herein through the U.S. Army Medical Research Acquisition Activity (USAMRAA). The following Laboratory will be the focus of cooperative research conducted under this agreement:

LTC Barbara Larcom
AFMS/SGRM
5201 Leesburg Pike, Suite 1401
Falls Church, VA 22041
Barbara.Larcom@pentagon.af.mil

B. ACCEPTANCE OF AWARD: The recipient is not required to countersign this assistance award. In case of disagreement, the recipient shall notify the Grants Officer and not assess the grant any costs until such disagreement(s) is resolved.

C. USAMRAA GENERAL TERMS AND CONDITIONS: This assistance agreement is subject to the USAMRAA General Terms and Conditions and to any special considerations as contained in the below mentioned Section titled "Special Terms and Conditions". These USAMRAA General Terms and Conditions are incorporated by reference with the same force and effect as if they were given in full text. The full text of the USAMRAA General Terms and Conditions may be accessed electronically at http://www.usamraa.army.mil/pages/index.cfm.

D. SPECIAL TERMS AND CONDITIONS

1. RESEARCH TECHNICAL REPORTING REQUIREMENTS
U.S. AIR FORCE SGR REPORTING REQUIREMENTS

USAF SGR reporting requirements for assistant agreement partners include monthly and final reports as stated below:

A. MONTHLY TECHNICAL PROGRESS REPORT: The recipient shall submit a Monthly Technical Progress Report covering work accomplished during each calendar month of performance. It shall be brief, factual, and informal, and shall be prepared in accordance with the sample report format on the following page. It shall contain the following:

Section I - Recipient and award information

Section II - A brief introduction covering the purpose and scope of the project at this stage and its relevance to the overall effort.

Section III - Using attached spreadsheet, provide overall progress to-date on listed tasks, milestones reached and deliverables completed. Use Section III on the form that follows to provide details on the following if more space is required:

- Describe scientific progress for the month in terms of the tasks or objectives listed in the statement of work for this assistant agreement. Explain deviations where this isn't possible. Include data where possible.
- Include a description of current problems (if any) that may impede performance along with proposed corrective action planned or underway; or anticipated problems that have a potential to impede progress, and what corrective action is planned should the problem materialize.
- Include pertinent data and graphs in sufficient detail to explain any significant results achieved.
- A report of any software or hardware (to include the source code) developed specifically for this assistant agreement.

Section IV - Include overall financial profile on the report period and of the project total to-date. Include the man-hours expended by position for the reporting period and cumulatively during the assistant agreement. Provide details as needed following the chart.

Section V - A description of work to be performed during the next reporting period. Use additional page(s) as needed to present a brief statement of plans, milestones expected, etc. Administrative comments such as a description of proposed site visits and participation in technical meetings, journal manuscripts in preparation, coordination with other organizations conducting related work, etc.

Monthly Technical Progress Reports shall be prepared by the seventh day following the month being reported, to be received within 10 days of the report month. The Monthly Technical Progress Report shall be submitted via email in Microsoft Word or Adobe PDF format to the following persons:

Grants Officer Representative (GOR):
Barbara Larcom, Lt Col, USAF, BSC
Office of the Assistant Surgeon General, Modernization
AF/SGRM
5201 Leesburg Pike, Suite 1401
Falls Church, VA 22041
Barbara.Larcom@pentagon.af.mil
- ------------------------------

Director
U.S. Army Medical Research Acquisition Activity (USAMRAA)
ATTN: MCMR-AAA-B (Juanita Bourne)
820 Chandler Street
Fort Detrick, MD 21702-5014
Juanita.Bourne@amedd.army.mil
- ------------------------------

The sample shown on the following page shall serve as the format for the monthly report. Each item of the report shall be completed or addressed.

Monthly Report Format

Section I include:
- Recipient name, phone, email and address:
- Award no:
- Project title:
- Report date:
- Reporting period:
- Principal investigator:
- PI contact info (phone and email):

Section II: Introduction on purpose and scope of this portion of the project effort:

Section III: Brief description of progress to-date (use this space for detailed explanations, graphs, charts, etc., Otherwise use the attached spreadsheet).

Section IV: Project expenditures to-date:

COST ELEMENTS	THIS MONTH	CUMULATIVE
Personnel		
Fringe Benefits		
Supplies		
Equipment		
Travel		
Other Direct Costs		
Subtotal		
Indirect Costs		
Fee		
Total		

In addition to the summary of costs required below, Section IV shall include:
- A report of any software or equipment procured with cost backup.
- Project-related trip reports, completed and included in the monthly report directly following completion of travel and shall include the following:
  - Dates of travel
  - Destination
  - Purpose of trip
  - Individual(s) contacted
  - Brief synopsis
  - Issues and challenges
  - Recommendations or outcome
  - Signature block

Section V - Milestones, tasks, deliverables, etc. expected to be completed in the next month.

B. MANUSCRIPTS/REPRINTS/ABSTRACTS: A copy of manuscripts or subsequent reprints resulting from the research shall be submitted the Grants Officer and the Grants Officer Representative simultaneously with the submission of the publication. Review of such manuscripts is for comments to the Principal Investigator, not for approval or disapproval.

C. FINAL REPORT:

Format Requirements for Final Reports

a. A final report summarizing the entire research effort, citing data in the annual reports (if any) and appended publications, shall be submitted at the end of the award performance period. The final report will provide a complete reporting of the research findings. Journal publications can be substituted for detailed descriptions of specific aspects of the research, but an original copy of each publication must be attached as an appendix and appropriately referenced in the text. All final reports must include a bibliography of all publications and meeting abstracts and a list of personnel (not salaries) receiving pay from the research effort.

b. Although there is no page limitation for the reports, each report shall be of sufficient length to provide a thorough description of the accomplishments with respect to the approved Statement of Work. Submission of an original and two copies of the report are required, as well as an electronic copy of the report are required. The final report shall be submitted no later than the 20th day after the completion of the research period. A copy of the final report shall be forwarded to the following address:

Commander, U.S. Army Medical Research and Materiel Command
ATTN: MCMR-ZC-I
504 Scott Street
Frot Detrick, MD 21702-5012

A copy of the final report in electronic version shall also be forwarded GOR via email to the following address:

Barbara.Larcom@pentagon.af.mil

c. All reports shall have the following elements in this order: front cover, Standard Form (SF 298), table of contents, introduction, body, key research accomplishments, reportable outcomes, conclusions, references, and appendices. Pages shall be consecutively numbered throughout the report. DO NOT RENUMBER PAGES IN THE APPENDICES BUT DO INCLUDE THE APPENDICES IN THE PAGE COUNT IN BLOCK 15 ON THE SF 298. Mark all pages of the report that contain proprietary or unpublished data that should be protected. DO NOT USE THE WORD "CONFIDENTIAL" WHEN MARKING DOCUMENTS. Indicate in your letter accompanying the report that the report contains proprietary or unpublished data, and that the distribution statement should indicate the limitations of the report.

FRONT COVER: Sample front cover provided at http://mrmc-www.army.mil. The Accession Document (AD) Number should remain blank (samples may only be viewed through secure servers).

STANDARD FORM 298: Sample SF 298 provided at http://mrmc-www.army.mil. The abstract in Block 13 must state the purpose, scope, major finding, and be an up-to-date report of the progress in terms of results and significance. Subject terms are keywords that may have previously assigned to the proposal abstract or are keywords that may be significant to the research. The number of pages shall include all pages that have printed data (including the front cover, SF 298, table of contents, and all appendices). Missing or incorrect page numbers will delay processing of reports.

TABLE OF CONTENTS: Sample table of contents provided at http://mrmc-www.army.mil.

INTRODUCTION: Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

BODY: This section of the report shall describe the research accomplishments associated with each task outlined in the approved Statement of Work. Data presentation shall be comprehensive in providing a complete record of the research findings for the period of the report. Appended publications and/or presentations may be substituted for detailed descriptions but must be referenced in the body of the report. If applicable, for each task outlined in the Statement of Work, reference appended publications and/or presentations for details of result findings and tables and/or figures. The report shall include negative as well as positive findings. Include problems in accomplishing any of the tasks. Statistical tests of significance shall be applied to all data whenever possible. Figures and graphs referenced in the text may be embedded in the text or appended. Recommended changes or future work to better address the research topic may also be included, although changes to the original Statement of Work must be approved by the Contracting Officer. This approval must be obtained prior to initiating any change to the original Statement of Work.

KEY RESEARCH ACCOMPLISHMENTS: Bulleted list of key research accomplishments emanating from this research.

REPORTABLE OUTCOMES: Provide a list of reportable outcomes that have resulted from this research to include:

- Manuscripts, Abstracts and presentations
- Patents and licenses applied for and/or issued
- Degrees obtained that are supported by this award
- Development of cell lines, tissue or serum repositories
- Infomatics such as databases and animal models, etc.
- Funding applied for based on work supported by this award
- Employment or research opportunities applied for and/or received based on experience/training supported by this award

CONCLUSIONS: Summarize the results to include the importance and/or implications of the completed research and when necessary, recommend changes on future work to better address the problem. A "so what" section that evaluates the knowledge as a scientific or medical product shall also be included in the conclusion of the report.

REFERENCES: List all references pertinent to the report using a standard journal format (i.e. format used in Science, Military Medicine, etc.).

APPENDICES: Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

BINDING: Because all reports are entered into the Department of Defense Technical Reports database collection and are microfiched, it is recommended that all reports be bound by stapling the pages together in the upper left hand corner. All original reports shall be legible and contain original photos/illustrations. Figures shall include figure legends and be clearly marked with figure numbers.

2. ADVANCE PAYMENTS AND FULL FUNDING (NOV 2000) (USAMRAA)

a. Payments. Advance payments will be made to the recipient. Questions relative to payment issues involving Defense Finance and Accounting Service shall be directed to the Contract Specilaist's name stated in Block 6 of the SF26 face page..

b. Electronic Funds Transfer. All advance payments to the recipient will be made by electronic funds transfer (EFT). The recipient shall contact the

Defense Finance and Accounting System (DFAS) named on the face page of this award to make arrangements for EFT. Failure to do so may result in nonpayment.

c. If the recipient fails to perform, the Grants Officer shall notify DFAS in writing to withhold payments.

d. Advance Payment Schedule

Year One $3,200,000

Amount	On or About
$1,000,000	Upon execution of this award
$733,334	1 January 2006
$733,333	1 April 2006
$733,333	1 July 2006

e. Financial Reporting Requirements: The recipient shall submit on a quarterly basis a Standard Form 272, Federal Cash Transactions Report (form available on web site http://www.usamraa.army.mil). Each report shall be submitted to the U.S. Army Medical Research Acquisition Activity, ATTN: MCMR-AAA-B, 820 Chandler Street, Fort Detrick MD 21702-5014 in accordance with the following schedule:

Period Covered	Due Date
Jan - Mar	15 Apr
Apr - Jun	15 Jul
Jul - Sep	15 Oct
Oct - Dec	15 Jan

f. Interest Bearing Account. Unless exempted by applicable Treasury-State agreements in accordance with the Cash Management Improvement Act (CMIA) (31 U.S.C. 3335), the recipient shall deposit all advance payments in an interest bearing account. Interest over the amount of $250 per year shall be remitted annually to the Department of Health and Human Services, Payment Management System, P.O. Box 6021, Rockville, MD 20852. A copy of the transmittal letter stating the amount of interest remitted shall be sent to the U.S. Army Medical Research Acquisition Activity, ATTN:MCMR-AAA-B, 820 Chandler Street, Fort Detrick, MD 21702-5014.

3. PROHIBITION OF USE OF LABORATORY ANIMALS (OCT 2003) (USAMRAA)

** PROHIBITION - READ FURTHER FOR DETAILS **

Notwithstanding any other provisions contained in this award or incorporated by reference herein, the recipient is expressly forbidden to use or subcontract for the use of laboratory animals in any manner whatsoever without the express written approval of the US Army Medical Research and Materiel Command, Animal Care and Use Office. You will receive written approval to begin research under the applicable protocol proposed for this award from the US Army Medical Research and Materiel Command, Animal Care and Use Office under separate letter to the recipient and Principal Investigator. A copy of this approval will be provided to the US Army Medical Research and Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in the termination of the award.

4. PROHIBITION OF USE OF HUMAN SUBJECTS (OCT 2003) (USAMRAA)

** PROHIBITION - READ FURTHER FOR DETAILS **

Research at funded institutions using human subjects may not begin until the U.S. Army Surgeon General's Human Subjects Research Review Board (HSRRB) approves the protocol. Written approval to begin research or subcontract for the use of human subjects under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HSRRB, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to the US Army Medical Research Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award.

5. PROHIBITION OF USE OF HUMAN ANATOMICAL SUBSTANCES (OCT 2003) (USAMRAA)

** PROHIBITION - READ FURTHER FOR DETAILS**

Research at funded institutions using human anatomical substances may not begin until the U.S. Army Surgeon General's Human Subjects Research Review Board (HSRRB) approves the protocol. Written approval to begin research or subcontract for the use of human anatomical substances under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HSRRB, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to the US Army Medical Research Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award.

6. PROHIBITION OF USE OF HUMAN CADAVERS (OCT 2003) (USAMRAA)

** PROHIBITION - READ FURTHER FOR DETAILS**

Research at funded institutions using human cadavers may not begin until the U.S. Army Surgeon General's Human Subjects Research Review Board (HSRRB) approves the protocol. Written approval to begin research or subcontract for the use of human cadavers under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HSRRB, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to the US Army Medical Research Acquisition Activity for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award.

7. DELIVERABLES:

Deliverablies shall be provided in accordance with the schedule stated on Page 13 of the proposal dated 5 July 2005.

CONTRACTOR SAFETY AND REPORTING (BDRP) (MAR 1999) (USAMRAA)

a. The contractor shall operate under established safety programs for all biosafety levels of work as identified in the Safety Program Plan, which is incorporated in this contract. These safety programs shall ensure that personnel, facilities, and the environment are protected from accidents and hazardous exposures.

b. The contractor shall conduct this contract work under established operating procedures which ensure that all individuals who have access to areas for storage, handling, and disposal of etiologic agents are trained and are thoroughly familiar with safety requirements. Such procedures shall assure full compliance with the regulatory standards cited above.

c. The contractor shall conduct an inspection and report the results of all required biosafety inspections for all Research, Development, Test, or Evaluation work in accordance with the below listed timeframes. As a minimum the safety inspections shall address those factors identified in the Safety Program Plan.

1. For Biosafety Level (BL) 1 and 2:

Time	Inspector
Preaward	Government designated Biosafety Officer
Quarterly	First line supervisor
Annual	Contractor safety personnel

2. For Biosafety Level (BL) 3:

Time	Inspector
Preaward	Government designated Biosafety Officer
Monthly	First line supervisor
Annual	Government designated Biosafety Officer

3. For Biosafety Level (BL) 4:

Time	Inspector
Preaward	Government designated Biosafety Officer
Monthly	First line supervisor
Semiannual	Government designated Biosafety Officer

4. Copies of all biosafety inspection reports will be distributed as follows:
Original:
In the contractor's records (Retained for at least three years)
One copy to the following:
U.S. Army Medical Research and Materiel Command
ATTN: MCMR-RCQ-S
504 Scott Street
Fort Detrick, Maryland 21702-5012
U.S. Army Medical Research and Materiel Command
ATTN: MCMR-PLD
504 Scott Street
Fort Detrick, Maryland 21702-5012
U.S. Army Medical Research Acquisition Activity
ATTN: MCMR-AAA
820 Chandler Street
Fort Detrick, Maryland 21702-5014

ETIOLOGIC AGENTS--BIOLOGICAL DEFENSE RESEARCH PROGRAM (MAR 1999) (USAMRAA)

a. For purpose of this contract etiologic agent--biological defense program is defined as: any viable microorganism, or its toxin which causes or may cause human disease, including those agents listed in 42 CFR 723 of the Department of Health and Human Services regulations, and any agent of biological origin that poses a degree of hazard to those agents and is further identified by the U.S. Army as a threat agent. The contractor shall comply with the following when working with etiologic agents:
1. 29 Code of Federal Regulations 1910
2. Occupational Health Standards, and the U.S. Department of Health and Human Services (DHHS)
3. DHHS Publication No. 93-8395, Biosafety in Microbiological and Biomedical Laboratories, 1993, as amended

4. 32 CFR 626 Biological Defense Safety Program
5. 32 CFR 627 Biological Defense Safety Program
b. Etiologic agents shall be packaged, labeled, shipped, and transported in accordance with applicable Federal, state and local laws and regulations, to include:
1. 42 CFR 72 (Interstate Shipment of Etiologic Agents)
2. 49 CFR 172 and 173 (Department of Transportation)
3. 9 CFR 122 (USDA Restricted Animal Pathogens)
4. International Air Transport Association Dangerous Goods Regulations.
5. The United States Postal Service shall not be used for transportation of BDRP activities involving etiologic agents.

EMERGENCY COORDINATION AND REPORTING (BDRP) (MAR 1999) (USAMRAA)

a. The contractor shall review the Emergency Response Plan/Safety Program Plan annually, during the month of July, in consultation with each participating external support agency. The Emergency Response Plan shall be formally revised, where necessary, to incorporate current emergency support requirements. The revised Emergency Response Plan (with the agreements for emergency support as appendices) shall be formalized in writing. A copy of the revision shall be retained in your organizational safety office.
b. The contractor shall submit a letter report documenting the outcome of the annual review of its Emergency Response Plan. The report shall include the dates of the annual review and coordination, and shall identify and describe all provisions that represent changes to the initial Emergency Response Plan or the previous year's annual report. The report shall be submitted no later than August 1 of each year, beginning with the first August during the performance of your contract.
c. All reports identified in this provision shall be submitted to the following address:
U.S. Army Medical Research and Materiel Command
ATTN: MCMR-RCQ-S
504 Scott Street
Fort Detrick, Maryland 21702-5012

SIGA

Contact:
Dr. Bernard L. Kasten
SIGA Technologies, Inc.
CEO
bkasten@siga.com
(212) 672-9100

SIGA ANNOUNCES A $3.2 MILLION CONTRACT WITH THE UNITED STATES ARMY MEDICAL RESEARCH AND MATERIAL COMMAND

New York, September 27, 2005 -- SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that it has entered into a $3.2 million, one year contract with the United States Army Medical Research and Material Command (USAMRMC). The agreement, for the rapid identification and treatment of anti-viral diseases, is funded through the United States Air Force (USAF). SIGA's efforts will aid the USAF Special Operations Command in its use of computational biology to design and develop specific countermeasures against the biological threat agents Smallpox and Adenovirus. Smallpox is a Center for Disease Control and Prevention (CDC) Category A biothreat agent, and Adenovirus is a cause of significant respiratory infectious disease, both of which may impair the combat readiness of USAF Personnel.

SIGA's computational approach to the development of countermeasures is designed to interface with USAF programs for the identification of potential agents of bioterrorism, and will provide a key building block in the foundation of a rapid response capability to biological threat agents. War-fighters and special operations forces, in particular, may be called upon to operate in environments containing known or unknown pathogens. Until these pathogens can be accurately identified and neutralized, our war fighters, Special Operations Forces and our nation remain vulnerable to the release of both natural and engineered viral pathogens.

"I am very excited about our relations with the USAF and SIGA's ability to participate in an effort which, I believe, is of crucial importance to our nation," said SIGA's CEO, Dr. Bernard L. Kasten. "I see a clear opportunity to continue working with the USAF in the future and to further advance SIGA's antiviral counter measure programs."

"We welcome the opportunity to work with our USAF colleagues to develop this important biological defense capability", said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA has the potential to become a significant force in the discovery of vaccine and pharmaceutical agents to fight emerging pathogens. SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria and emerging pathogens. SIGA's vaccine and drug platforms are based on its pioneering research into the structure, function and processing of bacterial surface proteins. In addition to smallpox, SIGA also has antiviral programs targeting other Category A pathogens which cause hemorrhagic fevers. Included are the arenaviruses (Lassa Fever Virus, Junin, Macupo, Guanarito, and Sabia), Lymphocytic choriomeningitis virus (LCMV), Dengue, and the filoviruses, Ebola and Marburg. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

Forward-looking statements

This Press Release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, and (d) SIGA may not be able to secure funding from anticipated government

contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection, for its products and (f) unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release and the above mentioned presentation, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov.

Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made and except for our obligations under the U.S. federal securities laws, we undertake no obligation to publicly update any forward-looking statements as a result of new information, future events or otherwise.

# # #